...Okay. Good morning, everyone, and welcome. Welcome those of you here at -- in Orlando at ASH, and welcome those at the webcast. Apologies for the late start. We had to adhere to certain guidelines from ASH, and there was no way to schedule this. And two of our speakers were busy presenting actually scientific data at the meeting. So we were forced to start a little bit late. So thank you for your patience. I'm sure you had an opportunity to grab some lunch. We're going to spend the next 45 minutes or so reviewing data from our 989. We're going to call it 989 for short program with you. I think this data, some of it was presented in June of this year at AHA in patients with ET. And yesterday and today, you heard from two of our speakers today about the translational data and the data in MF. We think this is a really important moment for patients with MPNs and for Incyte. We think 989 not only has the potential to redefine the standard of care in patients with MPNs, but to really redefine...
